Rentosertib decreases predicted biological age across various regimens as measured by most aging clocks, most significantly in the 30 mg BID group and in week 4. (IMAGE)

InSilico Medicine

Rentosertib decreases predicted biological age across various regimens as measured by most aging clocks, most significantly in the 30 mg BID group and in week 4.

Caption

In the current study, researchers evaluated serum proteome profiles from 42 trial participants across 2,841 proteins. The team applied six independently developed proteomic aging clocks, including ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT, and PAOPAC. Despite relying on diverse methodologies and training criteria, all six clocks consistently exhibited a trend toward reversed biological age among rentosertib-treated patients compared to placebo. The peak effect is observed at Week 4 in participants receiving 30 mg BID with approximately 3–4 years reversal in biological age and up to 6 years in a certain aging clock.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.